Clinical Trials Browser

Neoplasms, Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms, Venous Thromboembolism

NCT02566304 2025-04-24

Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Hodgkin Disease, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03297359 2024-01-23

WAVe

Phase 2 Terminated

92 enrolled

Classical hematologyOther

Neoplasms, Obesity, Venous Thromboembolism

NCT00931606 2023-09-13

MK-7962-012

Phase 2 Terminated

30 enrolled 32 charts

Classical hematology

Anemia, Neoplasm Metastasis, Neoplasms

NCT03944447 2022-06-02

OMNI-Can

Phase 2 Unknown

200,000 enrolled

Classical hematology

Chronic Traumatic Encephalopathy, Brain Injuries, Traumatic, COVID-19, Acquired Immunodeficiency Syndrome, Amyotrophic Lateral Sclerosis, Anemia, Sickle Cell, Anxiety Disorders, Autistic Disorder, Bipolar Disorder, Colitis, Ulcerative, Crohn Disease, Depression, Epilepsy, Fibromyalgia, Tourette Syndrome, Glaucoma, Hepatitis C, Sleep Initiation and Maintenance Disorders, Multiple Sclerosis, Opioid-Related Disorders, Neoplasms, Parkinson Disease, Seizures, Stress Disorders, Post-Traumatic, Inflammatory Bowel Diseases, Coronavirus Infections, Severe Acute Respiratory Syndrome, Chronic Pain

Clinical Trials

ASPIRE

Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

WAVe

MK-7962-012

OMNI-Can

Avatrombopag for Thrombocytopenia in People With Cancer

Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT

FENSY

AVERT

ALICAT

DISOLVE

Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer

Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer

The Efficacy of Intravenous Iron for the Treatment of Anemia in Cancer Patients

Cord Blood Stem Cell Transplantation Study (COBLT)

Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome

HaemOPtimal

Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer

Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)

Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain

Darbepoetin Alfa With or Without Intravenous (IV) Iron

Darbepoetin Alfa and Anemia of Cancer

Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)

Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure

Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies

A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy

Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy

Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy

Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks

A Study to Determine the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia Caused by Advanced Cancer

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in Patients With Anemia as a Result of Advanced Cancer and Treatment With Aggressive Chemotherapy

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia as a Result of Cancer Treatment With Cisplatin, a Platinum-containing Chemotherapy Drug

Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia

A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy

PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy

Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies

Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy

Evaluation of Iron Supplementation During Darbepoetin Alfa Treatment in Prophylaxis of Severe Anaemia Chemo-Induced